BRAF and tenosynovial giant cell tumor, diffuse type: FDA approved drugs include pexidartinib (PLX3397) [4], a colony stimulating factor 1 receptor kinase (CSF1R) inhibitor for treatment of tenosynovial giant cell tumours, and vemurafenib (PLX4032) [5], a serine/threonine-protein kinase B-Raf (B-Raf) inhibitor for late-stage melanoma (Figure 1).